n
the Special Topics analysis of obesity research in the past
decade, Dr. Claude Bouchard ranks at #13 among the 25
most-cited researchers in this specialized field, with 123
papers cited a total of 2,077 times at the time of the
analysis. In addition, Dr. Bouchard’s work is well
represented in the ISI
Essential
Science Indicators Web
product, with 204 papers cited a total of 3,418 times to date
in Clinical Medicine; 119 cited a total of 2,033 times in
Biology & Biochemistry; and 13 papers cited a total of 174
times in Agricultural Sciences. Dr. Bouchard is the Executive
Director of the Pennington Biomedical Research Center at
Louisiana State University in Baton Rouge. He recently spoke
with Special Topics correspondent Gary Taubes about his highly
cited work.
|
According
to this Special Topics analysis, your most influential paper of the
past decade has been "Waist circumference and abdominal sagittal
diameter: best simple anthropometric indexes of abdominal visceral
adipose tissue accumulation and related cardiovascular risk in men and
women," (American Journal of Cardiology 73[7]: 460-8; 1
March 1994). What did that paper say and why has it been so
influential?
I'm surprised this has been so highly cited, although it is an
interesting paper. I was only a co-author on this paper, which was
nurtured by my colleague Dr. J.R. Despres. We showed that waist
circumference was as good if not better an estimator of internal
abdominal fat than sagittal diameter, but the difference between the
two is really small. Abdominal circumference seems to perform a bit
better and is simpler to obtain, but for clinical reasons we said we
better use waist circumference. It's like
body mass index in that it’s only a surrogate for the amount of
adiposity but it works pretty well in a clinical setting.
Considering
your surprise, what would you consider your most influential work?
In obesity, that would probably be a paper in the New England
Journal of Medicine, an overfeeding study with identical twins,
published in 1990. ("The response to long-term overfeeding in
identical twins," NEJM 322[21]: 1477-82; 24 May 1990.)
What
was the purpose of that research and what were the results?
What I was looking for was an experimental demonstration that genes
were involved in the response of the human body to an affluence of
calories. We had heritability estimates based on population studies. I
was looking for an experimental way to establish whether genes are
involved or not. Here we were fortunate enough to have the
collaboration of 12 pairs of identical twins, all young males in their
early 20s. All were lean, with no family history of obesity, so they
were not considered at risk for obesity. We took two weeks to assess
what they were normally eating, while remaining weight-stable, and
then we measured them for many phenotypes and many metabolic markers.
Then we began an overfeeding experiment. We isolated them in a section
of a dormitory that had been reserved for us on the campus at Laval
University, in Quebec City, and we fed them 1,000 calories per day
more than what they would eat normally. We did this six days a week.
On the seventh day, they ate the baseline diet. We did that for 100
days. So overall there were 84 days of overfeeding, and each twin had
to handle an extra 84,000 calories. We kept them sedentary, as well.
It was a very complex study. It turned out that they gained weight, of
course. All of them. The average weight gain was 7 kilograms.
The remarkable thing was that there was a huge range, a three-fold
range, between high gainers and low gainers. Some twins gained
significantly more weight than others under the same challenge. But we
had three and half times more variation between pairs of twins than we
had within members of the same pair. That suggested that being
genetically similar meant a more similar response to caloric overload.
And that was a pretty strong demonstration, the first in humans, that
genes make a difference.
Did
you follow up on the experiment to see whether they retained the
weight and whether that, too, had a genetic component?
We did, but that was not in the New England Journal of
Medicine article. It was published later in Metabolism. We
re-measured these twins, four months after the completion of the study
and then five years later. Four months after the end of the study,
they were all within one kilogram of their baseline. Even the high
gainers had reverted back. I think this is largely because they went
back to their natural environment, to their friends, their old habits,
and fell into the same groove and their body weight was at that level
within that groove. Five years later, they were still at their normal
weight. We had the same resemblance within pairs of twins. They had
gained a little bit as you expect when they age. But they were
perfectly normal otherwise. We also did the opposite experiment
subsequently: losing weight for overweight or obese identical twins
and we recovered exactly the same phenomenon. That paper was published
in Obesity Research.
Why
did you choose the New England Journal of Medicine for the
first paper, Metabolism for the second, and Obesity Research
for the third?
The first one was of very general interest, because it touched upon
the predisposition to gain weight in the population. That's why I
submitted it to the New England Journal of Medicine. The second
dealt more with metabolism. We were asking questions not only about
weight but also about blood pressure, glucose intolerance, etc. That's
why I elected to send that to Metabolism. As for the third one,
Obesity Research, I'll be frank with you: I was involved in the
founding of this journal. I decided to provide support to the journal
and I submitted it there. It has also been quite highly cited.
What
has been the biggest challenge in your obesity research?
It's associated with the fact that we are trying to identify the
genes and mutations responsible for bestowing a predisposition to
obesity. When I began this research 20 years ago, I thought that only
a few genes would be involved. If you could identify which they were,
you could predict who would become obese or at least who was at risk.
Now it turns out that this predisposition seems to be determined by a
much larger number of genes and each seems to have only a small
effect. It becomes considerably more challenging to undertake the
genetic dissection of this predisposition for obesity. If you have 30
genes and each contributes one, two, or three percent of the risk,
then your experiments are usually not powerful enough to detect them.
And you miss them or find them and think their effect is so small that
it’s probably not important. In reality, it may be important and
these effects may be amplified if you have several of these risk genes
together in the same individual. But it is very hard to draw an
accurate picture of these genes at the moment. It's been very
frustrating. My lab has been working on this for quite a while. We've
probably looked at 50 different genes and we're still not able to draw
an integrated picture of which genes are making a difference.
Are
there other areas of obesity research in which progress has come
easier?
Well, yes. While it's been slow in genetics, it has been fast in
the definition of the pathways and the molecular biology of the
pathways regulating energy balance and adipogenesis. We have made
enormous advances there. That’s one thing.
Do
you think that most of the key pathways have been identified?
I don't think we have them all. I think we have the majority. Every
month we see a report in either Science or Nature of a
new fat gene, an obesity gene, a new pathway. And it keeps going on
and on. But we probably have the majority by now. We probably have the
strongest ones: the leptin, NPY, AGRP, and melanocortin pathways.
These are very strong loops in the regulation of energy balance. But
there are still undoubtedly some more to uncover. It’s a fascinating
field. And it's one that has changed dramatically in the last 10
years.
What
do you think the next five years is likely to bring in obesity
research?
Well, there are many labs now working intensely in the field
compared to 20 years ago. Then there was just a handful and obesity
was not attracting the best minds in molecular biology and genetics.
Now it is. So you have hundreds of labs now working on research that
will have a bearing on energy balance and obesity and the
complications of obesity. So in the next five years, it's bound to be
even more exciting in generating new molecules and perhaps new
advances in pharmacotherapy. Advances in molecular biology will
provide new targets. Industry will be taking advantage of that to
produce more powerful pharmacotherapies than the ones we have now.
From the basic science point of view, I have the feeling that
advances in the sequencing of the human genome and the mouse genome,
together with all the tools we have with transgenic mice and knockout
mice, will enable us to define in more refined ways how these pathways
interact. They appear to be very redundant, but they may have more
specificity than we think. Another five years may give us plenty of
advances to understand that specificity and see how it applies to
human beings. The last frontier will be undoubtedly the genetic
dissection of this complex profile: what are the genes that put
newborns at risk for obesity? And is there anything we can do early on
to prevent them from going that route?
Are
you optimistic?
I'm optimistic about the research but not about the prevention
of obesity. I don’t see the population changing its lifestyle so
that everyone becomes physically active and adopt a prudent diet.
We're not going to shift from cars back to bicycles and walking
anytime soon. And meanwhile the prevalence of obesity (BMI > 30)
may go from 22% to 25%, 30%, or 35%, and maybe even more. Where is it
going to stop? Pharmacotherapy for a good fraction of the population
may be an unavoidable solution. To be honest, I'm a little bit
pessimistic about our ability to deal with the problem at the national
level.
Dr. Claude Bouchard
Pennington Biomedical Research Center
Louisiana State University
Baton Rouge, LA, USA
|
ESI Special Topics,
March 2002
Citing URL - http://www.esi-topics.com/obesity/interviews/ClaudeBouchard.html
|
|